Clin Pharmacol Ther. 2008 Apr;83(4):622-6. Epub 2008 Jan 23.

Assessing abuse liability during drug development: changing standards and expectations.

Source

Clinical Pharmacology Group, DecisionLine Clinical Research Corporation, Toronto, Ontario, Canada. k.schoedel@dlcrc.com

Abstract

As public health concerns have changed, regulatory expectations for assessing abuse liability of new central nervous system (CNS) drugs have increased. All CNS-active drugs with any properties indicating stimulant, depressant, hallucinogenic, or mood-elevating effects will require an evaluation of abuse liability. Abuse liability assessment involves the collection, analysis, and interpretation of data on chemistry and tampering, animal behavioral pharmacology, clinical trial adverse events (AEs), diversion and overdose, and potentially reinforcing (subjective) effects in recreational drug users.

PMID:: 18212799; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Labome Researcher Resource - ExactAntigen/Labome

Medical

Supplemental Content

Related citations

Review Assessment of abuse liability of stimulant drugs in humans: a methodological survey. [Drug Alcohol Depend. 1991]
Review Assessment of abuse liability of stimulant drugs in humans: a methodological survey.
Foltin RW, Fischman MW. Drug Alcohol Depend. 1991 Jun; 28(1):3-48.
Review Guidelines and methodological reviews concerning drug abuse liability assessment. [Drug Alcohol Depend. 2003]
Review Guidelines and methodological reviews concerning drug abuse liability assessment.
Balster RL, Bigelow GE. Drug Alcohol Depend. 2003 Jun 5; 70(3 Suppl):S13-40.
Methods for the assessment of abuse liability of psychomotor stimulants and anorectic agents in humans. [Br J Addict. 1991]
Methods for the assessment of abuse liability of psychomotor stimulants and anorectic agents in humans.
Foltin RW, Fischman MW. Br J Addict. 1991 Dec; 86(12):1633-40.
The necessity and utility of abuse liability evaluations in human subjects. [Br J Addict. 1991]
The necessity and utility of abuse liability evaluations in human subjects.
Vocci FJ. Br J Addict. 1991 Dec; 86(12):1537-42.
Perspectives and future on testing for abuse liability in humans. [Br J Addict. 1991]
Perspectives and future on testing for abuse liability in humans.
Camí J. Br J Addict. 1991 Dec; 86(12):1529-31.

See reviews... See all...

Cited by 3 PubMed Central articles

Review Abuse liability assessment of tobacco products including potential reduced exposure products. [Cancer Epidemiol Biomarkers Prev. 2009]
Review Abuse liability assessment of tobacco products including potential reduced exposure products.
Carter LP, Stitzer ML, Henningfield JE, O'Connor RJ, Cummings KM, Hatsukami DK. Cancer Epidemiol Biomarkers Prev. 2009 Dec; 18(12):3241-62.
Review Principles of laboratory assessment of drug abuse liability and implications for clinical development. [Drug Alcohol Depend. 2009]
Review Principles of laboratory assessment of drug abuse liability and implications for clinical development.
Carter LP, Griffiths RR. Drug Alcohol Depend. 2009 Dec 1; 105 Suppl 1:S14-25. Epub 2009 May 14.
Sex differences in drug-related stress-system changes: implications for treatment in substance-abusing women. [Harv Rev Psychiatry. 2009]
Sex differences in drug-related stress-system changes: implications for treatment in substance-abusing women.
Fox HC, Sinha R. Harv Rev Psychiatry. 2009; 17(2):103-19.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Assessing abuse liability during drug development: changing standards and expect...
Assessing abuse liability during drug development: changing standards and expectations.
Clin Pharmacol Ther. 2008 Apr ;83(4):622-6. Epub 2008 Jan 23 .

PubMed
Actions of amphetamine derivatives and cathinone at the noradrenaline transporte...
Actions of amphetamine derivatives and cathinone at the noradrenaline transporter.
Eur J Pharmacol. 2003 Aug 22 ;476(1-2):31-4.

PubMed
Expression pattern and functional relevance of epidermal growth factor receptor ...
Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors?
Am J Gastroenterol. 2009 Jan ;104(1):171-81.

PubMed
Inhibition of adult rat retinal ganglion cells by D1-type dopamine receptor acti...
Inhibition of adult rat retinal ganglion cells by D1-type dopamine receptor activation.
J Neurosci. 2009 Nov 25 ;29(47):15001-16.

PubMed
False-positive phencyclidine immunoassay results caused by venlafaxine and O-des...
False-positive phencyclidine immunoassay results caused by venlafaxine and O-desmethylvenlafaxine.
Clin Chem. 2002 ;48(4):676-7.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to: